<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               DOSAGE AND ADMINISTRATION<BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     Single-Agent Dosage Schedules<BR>                     <BR>                     <BR>                        <BR>                           <BR>                           <BR>                           Dosage Regimens<BR>                           <BR>                              Irinotecan hydrochloride injection should be administered as an intravenous infusion over 90 minutes for both the weekly and once every 3 week dosage schedules (see <BR>                                    Preparation of Infusion Solution<BR>                                 ). Single-agent dosage regimens are shown in Table 7.<BR>                              <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><BR>                                 <caption>Table 7. Single-Agent Regimens of Irinotecan Hydrochloride Injection and Dose Modifications </caption><BR>                                 <col/><BR>                                 <col/><BR>                                 <col/><BR>                                 <tbody><BR>                                    <tr><BR>                                       <td valign="top" rowspan="4" styleCode="     Rrule     ">&#160;&#160;<content styleCode="bold">Weekly Regimen<footnote ID="FOOT_2211">Subsequent doses may be adjusted as high as 150 mg/m<sup>2</sup> or to as low as 50 mg/m<sup>2</sup> in 25 to 50 mg/m<sup>2</sup> decrements depending upon individual patient tolerance.</footnote><BR>                                          </content><BR>                                       </td><BR>                                       <td valign="top" colspan="3">&#160;&#160;125 mg/m<sup>2</sup> IV over 90 min, d 1,8,15,22 then 2-wk rest</td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td align="center" valign="top" colspan="3">&#160;&#160;<content styleCode="bold">Starting Dose &amp; Modified Dose Levels<footnote ID="FOOT_2212">Provided intolerable toxicity does not develop, treatment with additional cycles may be continued indefinitely as long as patients continue to experience clinical benefit.</footnote> (mg/m<sup>2</sup>)</content><BR>                                       </td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td align="center" valign="top">&#160;&#160;Starting Dose</td><BR>                                       <td align="center" valign="top">&#160;&#160;Dose Level -1</td><BR>                                       <td align="center" valign="top">&#160;&#160;Dose Level -2</td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td align="center" valign="top">&#160;&#160;125</td><BR>                                       <td align="center" valign="top">&#160;&#160;100</td><BR>                                       <td align="center" valign="top">&#160;&#160;75</td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td valign="top" rowspan="4" styleCode="     Rrule     ">&#160;&#160;<content styleCode="bold">Once Every 3 Week Regimen<footnote ID="FOOT_2213">Subsequent doses may be adjusted as low as 200 mg/m<sup>2</sup> in 50 mg/m<sup>2</sup> decrements depending upon individual patient tolerance.</footnote><BR>                                          </content><BR>                                       </td><BR>                                       <td valign="top" colspan="3">&#160;&#160;350 mg/m<sup>2</sup> IV over 90 min, once every 3 wks<footnoteRef IDREF="FOOT_2212"/><BR>                                       </td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td align="center" valign="top" colspan="3">&#160;&#160;<content styleCode="bold">Starting Dose &amp; Modified Dose Levels (mg/m<sup>2</sup>)</content><BR>                                       </td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td align="center" valign="top">&#160;&#160;Starting Dose</td><BR>                                       <td align="center" valign="top">&#160;&#160;Dose Level -1</td><BR>                                       <td align="center" valign="top">&#160;&#160;Dose Level -2</td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td align="center" valign="top">&#160;&#160;350</td><BR>                                       <td align="center" valign="top">&#160;&#160;300</td><BR>                                       <td align="center" valign="top">&#160;&#160;250</td><BR>                                    </tr><BR>                                 </tbody><BR>                              </table><BR>                              <BR><BR><BR>A reduction in the starting dose by one dose level of irinotecan hydrochloride injection may be considered for patients with any of the following conditions: prior pelvic/abdominal radiotherapy, performance status of 2, or increased bilirubin levels. Dosing for patients with bilirubin >2 mg/dL cannot be recommended because there is insufficient information to recommend a dose in these patients. <BR>                              It is recommended that patients receive premedication with antiemetic agents. Prophylactic or therapeutic administration of atropine should be considered in patients experiencing cholinergic symptoms. See <BR>                                    PRECAUTIONS, General<BR>                                 .<BR>                           <BR>                           <BR>                        <BR>                     <BR>                     <BR>                        <BR>                           <BR>                           <BR>                           Dose Modifications<BR>                           <BR>                              Patients should be carefully monitored for toxicity and doses of irinotecan hydrochloride injection should be modified as necessary to accommodate individual patient tolerance to treatment. Based on recommended dose-levels described in Table 7, Single-Agent Regimens of irinotecan hydrochloride injection and Dose Modifications, subsequent doses should be adjusted as suggested in Table 8, Recommended Dose Modifications for Single-Agent Schedules. All dose modifications should be based on the worst preceding toxicity. <BR>                              A new cycle of therapy should not begin until the toxicity has recovered to NCI grade 1 or less. Treatment may be delayed 1 to 2 weeks to allow for recovery from treatment-related toxicity. If the patient has not recovered, consideration should be given to discontinuing this combination therapy. Provided intolerable toxicity does not develop, treatment with additional cycles of irinotecan hydrochloride injection may be continued indefinitely as long as patients continue to experience clinical benefit.<BR>                              <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><BR>                                 <caption>Table 8. Recommended Dose Modifications For Single-Agent Schedules<footnote ID="FOOT_2214">All dose modifications should be based on the worst preceding toxicity</footnote><BR>                                 </caption><BR>                                 <col width="19%"/><BR>                                 <col width="47%"/><BR>                                 <col width="17%"/><BR>                                 <col width="17%"/><BR>                                 <thead><BR>                                    <tr><BR>                                       <th valign="top" colspan="4" styleCode="     Botrule     "> A new cycle of therapy should not begin until the granulocyte count has recovered to &#8805;1500/mm<sup>3</sup>, and the platelet count has recovered to &#8805;100,000/mm<sup>3</sup>, and treatment-related diarrhea is fully resolved. Treatment should be delayed 1 to 2 weeks to allow for recovery from treatment-related toxicities. If the patient has not recovered after a 2-week delay, consideration should be given to discontinuing Irinotecan Hydrochloride Injection.</th><BR>                                    </tr><BR>                                    <tr><BR>                                       <th align="center" rowspan="2" styleCode="     Rrule     "> Worst Toxicity NCI Grade<footnote ID="FOOT_2215">National Cancer Institute Common Toxicity Criteria (version 1.0)</footnote> (Value)</th><BR>                                       <th align="center" styleCode="     Botrule          Rrule     "> During a Cycle of Therapy</th><BR>                                       <th align="center" valign="top" colspan="2" styleCode="     Botrule     "> At the Start of the Next Cycles of Therapy (After Adequate Recovery), Compared with the Starting Dose in the Previous Cycle<footnoteRef IDREF="FOOT_2214"/><BR>                                       </th><BR>                                    </tr><BR>                                    <tr><BR>                                       <th align="center" valign="top" styleCode="     Rrule     "> Weekly</th><BR>                                       <th align="center" valign="top" styleCode="     Rrule     "> Weekly</th><BR>                                       <th align="center" valign="top"> Once Every 3 Weeks</th><BR>                                    </tr><BR>                                 </thead><BR>                                 <tbody><BR>                                    <tr><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;No toxicity</td><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;Maintain dose level</td><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;&#8593; 25 mg/m<sup>2</sup> up to a maximum dose of 150 mg/m<sup>2</sup><BR>                                       </td><BR>                                       <td valign="top">&#160;&#160;Maintain dose level</td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;<content styleCode="bold">Neutropenia</content><BR>                                       </td><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;</td><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;</td><BR>                                       <td valign="top">&#160;&#160;</td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;1 (1500 to 1999/mm<sup>3</sup>)</td><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;Maintain dose level</td><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;Maintain dose level</td><BR>                                       <td valign="top">&#160;&#160;Maintain dose level</td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;2 (1000 to 1499/mm<sup>3</sup>)</td><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;&#8595; 25 mg/m<sup>2</sup><BR>                                       </td><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;Maintain dose level</td><BR>                                       <td valign="top">&#160;&#160;Maintain dose level</td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;3 (500 to 999/mm<sup>3</sup>)</td><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;Omit dose until resolved to &#8804; grade 2, then &#8595; 25 mg/m<sup>2</sup><BR>                                       </td><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;&#8595; 25 mg/m<sup>2</sup><BR>                                       </td><BR>                                       <td valign="top">&#160;&#160;&#8595; 50 mg/m<sup>2</sup><BR>                                       </td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;4 (&lt;500/mm<sup>3</sup>)</td><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;Omit dose until resolved to &#8804; grade 2, then &#8595; 50 mg/m<sup>2</sup><BR>                                       </td><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;&#8595; 50 mg/m<sup>2</sup><BR>                                       </td><BR>                                       <td valign="top" styleCode="     Botrule     ">&#160;&#160;&#8595; 50 mg/m<sup>2</sup><BR>                                       </td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;<content styleCode="bold">Neutropenic fever</content><BR>                                       </td><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;Omit dose until resolved, then &#8595; 50 mg/m<sup>2</sup> when resolved</td><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;&#8595; 50 mg/m<sup>2</sup><BR>                                       </td><BR>                                       <td valign="top" styleCode="     Botrule     ">&#160;&#160;&#8595; 50 mg/m<sup>2</sup><BR>                                       </td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;<content styleCode="bold">Other hematologic toxicities</content><BR>                                       </td><BR>                                       <td valign="top" colspan="3">&#160;&#160;Dose modifications for leukopenia, thrombocytopenia, and anemia during a cycle of therapy and at the start of subsequent cycles of therapy are also based on NCI toxicity criteria and are the same as recommended for neutropenia above.</td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;<content styleCode="bold">Diarrhea</content><BR>                                       </td><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;</td><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;</td><BR>                                       <td valign="top">&#160;&#160;</td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;1 (2&#8211;3 stools/day &gt; pretx<footnote ID="FOOT_2216">Pretreatment</footnote>)</td><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;Maintain dose level</td><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;Maintain dose level</td><BR>                                       <td valign="top">&#160;&#160;Maintain dose level</td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;2 (4&#8211;6 stools/day &gt; pretx)</td><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;&#8595; 25 mg/m<sup>2</sup><BR>                                       </td><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;Maintain dose level</td><BR>                                       <td valign="top">&#160;&#160;Maintain dose level</td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;3 (7&#8211;9 stools/day &gt; pretx)</td><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;Omit dose until resolved to &#8804; grade 2, then &#8595; 25 mg/m<sup>2</sup><BR>                                       </td><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;&#8595; 25 mg/m<sup>2</sup><BR>                                       </td><BR>                                       <td valign="top">&#160;&#160;&#8595; 50 mg/m<sup>2</sup><BR>                                       </td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;4 (&#8805;10 stools/day &gt; pretx)</td><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;Omit dose until resolved to &#8804; grade 2 then &#8595; 50 mg/m<sup>2</sup><BR>                                       </td><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;&#8595; 50 mg/m<sup>2</sup><BR>                                       </td><BR>                                       <td valign="top" styleCode="     Botrule     ">&#160;&#160;&#8595; 50 mg/m<sup>2</sup><BR>                                       </td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;<content styleCode="bold">Other nonhematologic<footnote ID="FOOT_2217">Excludes alopecia, anorexia, asthenia</footnote> toxicities</content><BR>                                       </td><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;</td><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;</td><BR>                                       <td valign="top">&#160;&#160;</td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;1</td><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;Maintain dose level</td><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;Maintain dose level</td><BR>                                       <td valign="top">&#160;&#160;Maintain dose level</td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;2</td><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;&#8595; 25 mg/m<sup>2</sup><BR>                                       </td><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;&#8595; 25 mg/m<sup>2</sup><BR>                                       </td><BR>                                       <td valign="top">&#160;&#160;&#8595; 50 mg/m<sup>2</sup><BR>                                       </td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;3</td><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;Omit dose until resolved to &#8804; grade 2, then &#8595; 25 mg/m<sup>2</sup><BR>                                       </td><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;&#8595; 25 mg/m<sup>2</sup><BR>                                       </td><BR>                                       <td valign="top">&#160;&#160;&#8595; 50 mg/m<sup>2</sup><BR>                                       </td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;4</td><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;Omit dose until resolved to &#8804; grade 2, then &#8595; 50 mg/m<sup>2</sup><BR>                                       </td><BR>                                       <td valign="top" styleCode="     Rrule     ">&#160;&#160;&#8595; 50 mg/m<sup>2</sup><BR>                                       </td><BR>                                       <td valign="top">&#160;&#160;&#8595; 50 mg/m<sup>2</sup><BR>                                       </td><BR>                                    </tr><BR>                                 </tbody><BR>                              </table><BR>                           <BR><BR><BR><BR>                           <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     Dosage in Patients with Reduced UGT1A1 Activity<BR>                     <BR>                        When administered as a single-agent, a reduction in the starting dose by at least one level of irinotecan hydrochloride injection should be considered for patients known to be homozygous for the UGT1A1*28 allele (see <BR>                              CLINICAL PHARMACOLOGY<BR>                            and <BR>                              WARNINGS<BR>                           ). However, the precise dose reduction in this patient population is not known and subsequent dose modifications should be considered based on individual patient tolerance to treatment (see Tables 7-8).<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     Preparation & Administration Precautions<BR>                     <BR>                        As with other potentially toxic anticancer agents, care should be exercised in the handling and preparation of infusion solutions prepared from irinotecan hydrochloride injection. The use of gloves is recommended. If a solution of irinotecan hydrochloride injection contacts the skin, wash the skin immediately and thoroughly with soap and water. If irinotecan hydrochloride injection contacts the mucous membranes, flush thoroughly with water.<BR>                        Several published guidelines for handling and disposal of anticancer agents are available.1–4<BR>                        <BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     Preparation of Infusion Solution<BR>                     <BR>                        Inspect vial contents for particulate matter and repeat inspection when drug product is withdrawn from vial into syringe. Irinotecan hydrochloride injection must be diluted prior to infusion. Irinotecan hydrochloride injection should be diluted in 5% Dextrose Injection, USP, (preferred) or 0.9% Sodium Chloride Injection, USP, to a final concentration range of 0.12 to 2.8 mg/mL. In most clinical trials, irinotecan hydrochloride injection was administered in 250 mL to 500 mL of 5% Dextrose Injection, USP. The solution is physically and chemically stable for up to 24 hours at room temperature (approximately 25º C, 77º F) and in ambient fluorescent lighting. Solutions diluted in 5% Dextrose Injection, USP, and stored at refrigerated temperatures (approximately 2° to 8°C, 36° to 46°F), and protected from light are physically and chemically stable for 48 hours. Refrigeration of admixtures using 0.9% Sodium Chloride Injection, USP, is not recommended due to a low and sporadic incidence of visible particulates. Freezing irinotecan hydrochloride injection and admixtures of irinotecan hydrochloride injection may result in precipitation of the drug and should be avoided. Because of possible microbial contamination during dilution, it is advisable to use the admixture prepared with 5% Dextrose Injection, USP, within 24 hours if refrigerated (2° to 8°C, 36° to 46°F). In the case of admixtures prepared with 5% Dextrose Injection, USP, or Sodium Chloride Injection, USP, the solutions should be used within 6 hours if kept at room temperature (15º to 30º C, 59º to 86º F). <BR>                        Other drugs should not be added to the infusion solution. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. <BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>